November 07, 2009 14:00 ET

Echosens Official Sponsor of Indian Symposium

PARIS, FRANCE--(Marketwire - Nov. 7, 2009) - Echosens, the French high-technology company specializing in non-invasive diagnostics in hepatology is the official sponsor of the Symposium held by Pr Sarin in the Famous Institute of liver and Biliary Sciences of New Delhi today. This symposium will focus on the non invasive diagnosis and management of hepatic fibrosis, with speakers from all around the world.

FibroScan®, an efficient and non-invasive diagnostic technique

The Fibroscan® powered by VCTE™ gives a unique capability to physician. This device specific to the liver, measures in a quantitative and reproducible way the "degree of hepatic fibrosis", from children to adults, of all shapes and sizes. With immediate result this non-invasive diagnostic method is a real revolution for liver diseases management, a revolution that Indian patients will be able to benefit from now.

Echosens will support the Indian market for the FibroScan®, a product commercially available since 2005 worldwide and selected by the community of hepatologists thanks to more than 250 independent publications. Fibroscan® is the first clinically validated device using Elastography. According to Richard Guillaume, CEO of Echosens, "With its non-invasive nature, its ease of use and its immediate results, FibroScan® has already revolutionized the medical practice of hepatologists in Europe and Asia, and is expected to experience the same success in India."

Echosens: Partner for diagnostic solutions in Hepatology

A French company founded in 2001 in Paris, Echosens is an international SME specializing in the field of hepatology. The company developed and manufactures the FibroScan® device, based on VCTE™ "Vibration Controlled Transcient Elastography". Echosens dedicates a significant part of its activity to Research in order to develop new medical devices and to open up new medical perspectives. The company works in close cooperation with health professionals and patients' associations to facilitate therapeutic follow up of patients. To date, 700 FibroScan® devices have been installed worldwide, including 157 in France. HAS (Health French authority) validated the Fibroscan® for the diagnosis of HCV and HIV-HCV

For more information:

Press kit available on demand

Contact Information